The Significance Of GFI1B Expression In Malignant Hematologic Diseases

Objesctive: To investigate the expression and significance of GFI1B in acute leukemia, chronic myeloid leukemia and myelodysplastic syndrome.Methods:1 Objects: Bone marrow or peripheral blood samples from 74 patients with acute leukemia (AL), 25 patients with chronic myeloid leukemia (CML), 9 patients with myelodysplastic syndrome(MDS)and 10 normal controls were analyzed.2 Real-time quantitative PCR was used to investigate the expression of GFI1B in AL, CML and MDS. The statistical analyses were performed to evaluate the effect of GFI1B expression values.Results:1 Expression of GFI1B mRNA1.1 Expression of GFI1B mRNA in patients with acute myelogenous leukemia(AML)1.1.1 Expression of GFI1B mRNA in patients with denovo and relapsed.48 denovo AML patients were evaluated for GFI1B mRNA expression, 42 were positive, with a positive rate of 85.7%. 10 normal controls were evaluated for GFI1B mRNA expression, 6 were positive, with a positive rate of 60.0%. The mRNA expression of GFI1B in denovo patients with AML was higher than that in normal control, with statistical significance(P<0.05). 6 patients with relapsed AML were evaluated for GFI1B mRNA expression, all patients were positive, with a positive rate of 100.0%. The mRNA expression of GFI1B in patients with relapsed AML was higher than that in denovo AML patients without statistical significance(P >0.05)and higher than that in normal control with statistical significance(P<0.05).1.1.2 Expression of GFI1B mRNA in AML patients who had achieved complete remission (CR)40 AML patients in CR were evaluated for GFI1B mRNA expression, 31 patients were positive, with a positive rate of 77.5%. The mRNA level of GFI1B in AML patients in CR was lower compared with denovo and relapsed AML patients, both with statistical significance (P<0.05), but higher compared with normal control without statistical significance(P >0.05). 10 AML patients in continuous complete remission (CCR) were evaluated for GFI1B mRNA expression, 7 were positive, with a positive rate of 70.0%. The mRNA level of GFI1B in AML patients in CR for less than 3 years and in AML patients in CCR were also lower than that in denovo and relapsed AML patients, both with statistical significanc(eP<0.05)and higher than that in normal control without statistical significance(P >0.05). The mRNA level of GFI1B in AML patients in CR for less than 3 years was higher compared with CCR patients , but without statistical significance(P >0.05)1.1.3 Expression of GFI1B mRNA in different subtypes of denovo cases of AMLThere are difference in the mRNA level of GFI1B in different denovo AML subtypes (M1-M7), the mRNA expression of GFI1B in M1,M2,M3and M5 subtypes was higher than that in normal control without statistical significance(P >0.05). 10 M4 patients were evaluated for GFI1B mRNA expression, all were positive, with a positive rate of 100.0%.The mRNA level of GFI1B in M4 subtypes was higher than that in normal control with statistical significance(P<0.05). All of 5patients with M6 subtypes GFI1B mRNA were positive, for GFI1B Mrna with a positive rate of 100.0%.The mRNA level of GFI1B in M6 subtypes was higher than that in normal control with statistical significance(P<0.05). All of 3 cases of M7 subtypes were positive for GFI1B mRNA expression, , with a positive rate of 100.0%.The mRNA level of GFI1B in M7 subtypes was higher than that in normal control with statistical significance(P<0.05).1.2 Expression of GFI1B mRNA in patients with acute lymphoblastic leukemia(ALL)7 denovo ALL patients were evaluated for GFI1B mRNA expression, 5 were positive, with a positive rate of 71.4%. 6 ALL patients in CR were evaluated for GFI1B mRNA expression, 4 were positive, with a positive rate of 66.7%. All of 3 relapsed ALL patients were positive for GFI1B mRNA expression, with a positive rate of 100.0%. The mRNA level of GFI1B showed no difference in denovo, relapsed and completely remitted ALL patients compared with normal control(P >0.05).1.3 Expression of GFI1B mRNA in patients with chronic myeloid leukemia15 out of 20 patients with CML-CP were positive for GFI1B mRNA expression, with a positive rate of 75.0%. The mRNA expression of GFI1B in CML-CP was higher than that in normal control without statistical significance(P >0.05)and lower than that in denovo or relapsed AML patients with statistical significance(P<0.05).5 patients with CML-BP were evaluated for GFI1B mRNA expression, all were positive, with a positive rate of 100%. The mRNA expression of GFI1B in patients with CML blastic phase was higher than that in normal control with statistical significance(P<0.05), higher than that in denovo AML patients and lowerr than that in relapsed AML patients without statistical significance(P >0.05).1.4 Expression of GFI1B mRNA in patients with myelodysplastic syndrome9 patients with myelodysplastic syndrome were evaluated for GFI1B mRNA expression, 7 were positive, with a positive rate of 77.8%. The mRNA expression of GFI1B in patients with myelodysplastic syndrome was lower than that in normal control. without statistical significance(P >0.05)2 The relationship between the expression of GFI1B and therapeutic efficacy in denovo acute leukemia patients The therapeutic efficacy in 55 of 58 denovo acute leukemia patients was evaluated (1 patient died early, 2patients gave up treatment).46 of 55 AL patients achieved complete hematological response (CR) after induction therapy, with a CR rate of 83.6%. 40 of 48 acute myelogenous lecukemia(AML) patients achieved complete hematological response (CR) after induction therapy ,the mRNA level of GFI1B in patient who have achieved CR was lower than that before treatment ,with statistical significance ( P<0.05 ) and highercompared with normal control and CCR patients without statistical significance(P >0.05). All of 8 patients of AML have not achieved complete hematological response (CR) after induction therapy were positive for GFI1B mRNA expression, with a positive rate of 100.0%. The mRNA level of GFI1B in patient who have not achieved CR was higher than that before treatment, and relapsed patients, both without statistical significance (P >0.05)but higher in comparison with normal control and CCR patients with statistical significance(P<0.05).6 of 7 in acute lymphoblastic leukemia(ALL) patients achieved complete hematological response (CR) after induction therapy, The mRNA level of GFI1B in CR patients showed no statistical differences compared with pre treatment, relapsed and CCR patients, and normal control(P >0.05).Conclusions:1 The mRNA expression of GFI1B in denovo acute myelogenous leukemia was significantly higher than that in normal control.The mRNA levels of GFI1B in recurrent patients were higher than normal control. The mRNA level of GFI1B in CR patients with acute myelogenous leukemia was lower than that in patients with denovo or relapsed AML without difference in comparison with normal control. The mRNA level of GFI1B in patients with acute myelogenous leukemia who had been CR for less than 3 years didn't differ from that in AML patients with CCR .The mRNA level of GFI1B in patients who have achieved CR was lower than that before treatment . The mRNA level of GFI1B in patients who have not achieved CR was lower than that before treatment and relapsed patients without statistical significance and higher than that in CR patients and normal control with statistical significance. Suggesting that GFI1B gene may be involved in the pathogenesis and progression of acute myelogenous leukemia. GFI1B expression may be down-regulated following remission of leukemia and up-regulated following relapse.2 There was difference of the mRNA level of GFI1B in different subtypes of denovo patients with acute myelogenous leukemia ( AML ) (M1-M7), the mRNA expression of GFI1B in M1,M2,M3and M5 subtypes of acute myelogenous lecukemia was higher than that in normal control without statistical significance. The mRNA level of GFI1B in M4 subtypes of acute myelogenous lecukemia was higher than that in normal control with statistical significance. The mRNA level of GFI1B in M6and M7 subtypes of acute myelogenous lecukemia was higher than that in normal control with statistical significance. Our date show that GFI1B plays an essential role in erythroleukaemia and megakaryocytic leukaemia.3 The mRNA level of GFI1B showed no statistical difference in patients with denovo, relapsed and CR acute lymphoblastic leukemia compared with normal control. Therefore, GFI1B gene may not become involved in ALL .4 The mRNA expression of GFI1B in patients with CML-CP identified with that in normal control and was lower than that in both denovo and relapsed patients with acute myelogenous leukemia . The mRNA expression of GFI1B in patients with CML-BP was higher compased with normal control, and patients with CML-CP with statistical significance. The mRNA expression of GFI1B in patients with CML -BP was higher than that in denovo patients with acute myelogenous leukemia and lower than that in patients with relapsed acute myelogenous leukemia without statistical significance. This suggests that GFI1B uppears to participate in the progression of CML. The outcome of CML may be deteriorated by positive or up-regulate GFI1B .5 Expression of GFI1B mRNA in patients with myelodysplastic syndrome was lower than that in normal control, without statistical significance.Therefore, GFI1B gene involvement may not leeome involved in the disturfed erythropoiesis of MDS patients.